Moving Upstream
Disease Prevention as a strategic opportunity for Irish Medtech Innovation
Ireland’s healthcare system, like many across Europe, is under increasing pressure due to an ageing population, rising chronic disease burden, and stretched resources.
This report, developed in partnership by Irish Medtech Skillnet, with Skillnet Ireland, and the guidance of the Irish Medtech, argues that upstream innovation prioritising early intervention, prevention, diagnostics, and the use of real-world evidence offers a transformative opportunity for the medtech sector to deliver more sustainable, cost-effective and person-centred healthcare.
Why Upstream and Why Now?
Moving upstream is not simply a health system aspiration; it is an economic and industry imperative.
Ireland’s Medtech sector is uniquely positioned as both a global exporter and a living testbed for upstream innovation, giving it strategic leverage to lead in prevention-focused healthcare. International and Irish evidence demonstrates that preventive action delivers strong returns:
- A national diabetes prevention programme could generate a 1.6x ROI and reduce disease incidence by up to 4.6% (Pierse et al., 2021).
- If preventable risk factors were systematically addressed, Ireland could gain an average of 2.1 additional years of life expectancy (OECD, 2024).
- Up to 70% of chronic disease spending can be avoided through earlier intervention and effective management (Department of Health, 2023).
This report complements detailed economic analysis from the WiFOR Institute (2025) on Chronic Limb-Threatening Ischaemia (CLTI), which showed that early Medtech intervention could reduce major amputations by 40% and deliver returns of €1.60–€2.10 for every euro invested. That study provides the quantitative foundation for the broader argument advanced here: that prevention-aligned medtech is both a public good and a commercial opportunity.